Protecting Life and Integrity in Research Act of 2025
Summary
HR2075 is an early-stage House bill that would ban federal funding for research using human fetal tissue from induced abortions. It is stuck in committee with no floor action since introduction in March 2025. The market data shows a broad 30-day decline across biomedical stocks, but $TMO and $DHR have moved -1.19% and +0.72% respectively in the past 7 days — not signaling acute legislative risk. The bill has zero direct appropriations and remains a low-probability risk factor for life sciences tool suppliers.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2075 is early-stage (referred to committee) with zero floor action since March 2025 — low near-term passage probability.
- 2.The bill restricts federal funding for a narrow research niche; the aggregate market impact on $TMO and $DHR is sub-1% of revenue.
- 3.Recent 7-day price moves are flat to slightly negative for biotech tools, but not driven by this legislation.
Market Implications
The market is not pricing this bill as a material risk. $TMO at $464.14 is down -1.19% over 7 days and -5.57% over 30 days — consistent with a broader sector pullback in life science tools, not a specific legislative overhang. $DHR at $178.52 is essentially flat over 7 days (+0.72%) and down -5.84% over 30 days. Investors should monitor committee hearing announcements for HR2075 or its companion S987 as the primary catalyst trigger. A hearing or markup would be the first signal of real legislative momentum. Until then, these stocks trade on fundamentals and broader biotech funding cycles.
Full Analysis
The 'Protecting Life and Integrity in Research Act of 2025' (HR2075) was introduced in the House on March 11, 2025, by Rep. Onder (R-MO) and 33 cosponsors. It has been referred to the Committee on Energy and Commerce and has seen zero legislative action since. A companion bill, S987, is in the Senate HELP Committee. This is an authorization bill — it prohibits federal funding but does not allocate any money itself. The bill carves out exceptions for research using fetal tissue from miscarriages or stillbirths and encourages development of 'new, ethical cell lines'. The mechanism is a funding restriction on NIH, CDC, and other federal agencies; the obligated parties are universities, hospitals, and research institutes that receive federal grants for human fetal tissue research. The direct consequence is reduced procurement from upstream suppliers like Thermo Fisher and Danaher, but the affected research niche is small relative to total life science research spend.
Structural winners and losers: The primary losers are companies with high exposure to academic and government research consumables — $TMO and $DHR. $VRTX (Vertex) and $GILD (Gilead) are biopharma firms that use cell-based assays in early drug discovery, but they rely predominantly on established cell lines (HEK293, HeLa, iPSCs) and induced pluripotent stem cells, not primary fetal tissue. Their exposure is minimal. $RHHBY (Roche) is a diversified diagnostics and pharma conglomerate with broad tools exposure via Roche Diagnostics; the fetal tissue niche is a rounding error. No pure-play tickers exist for fetal tissue research specifically — this is a sub-niche within academic life science tools.
Real market data analysis: Over the trailing 7 days (April 24-30), $TMO dropped 1.19% to $464.14, $DHR rose 0.72% to $178.52, $RHHBY fell 2.76% to $50.43, $VRTX fell 0.63% to $427.56, and $GILD fell 0.26% to $130.06. The 30-day trends show broad weakness: $TMO -5.57%, $DHR -5.84%, $GILD -6.68%, and $VRTX -4.25%. $RHHBY bucked the trend with +3.26% over 30 days. The 7-day moves do not correlate with HR2075 news (no new actions) and are more likely driven by broader sector rotation and earnings sentiment.
Timeline: The bill is at the earliest legislative stage — referred to committee with no hearings, markup, or floor schedule. With a Republican House majority and Democratic Senate, the probability of passage in the 119th Congress is low. The bill would need to pass both chambers and be signed by the President. Current status suggests it is a messaging bill, not a near-term market catalyst.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Prohibition of federal funding for research using human fetal tissue from induced abortions — applies to any federal department, agency, or office; indirectly restricts demand for research tools and services sold to federally funded institutions conducting such research.
Who must act
Universities, hospitals, and research institutes receiving NIH or other federal grants that currently conduct research using human fetal tissue from induced abortions, and their upstream suppliers of research consumables and services.
What happens
Reduction in federal grant-funded procurement of specialized cell culture media, antibodies, reagents, and custom biologicals used in fetal tissue research; federally funded researchers will shift to alternative models or discontinue projects, reducing overall lab consumables spend in this niche.
Stock impact
Thermo Fisher's Life Sciences Solutions segment (~$12B annual revenue) supplies antibodies, cell culture media, and reagents broadly; fetal-tissue-related research is a small fraction of total academic and biopharma demand, but the 'headwind' is already reflected in a 7-day -1.19% decline vs a broader market that is stable. Estimated annual revenue at risk in the low tens of millions — less than 0.3% of segment revenue.
What the bill does
Prohibition of federal funding for research using human fetal tissue from induced abortions — same mechanism; Danaher's life sciences platform (Beckman Coulter, Pall, Cytiva) sells instruments, filtration, and consumables to federally funded academic and government labs.
Who must act
Same obligated party as above: federally funded research institutions and their procurement budgets.
What happens
Reduction in grant-funded capital equipment and consumable purchases for specialized cell separation, culture, and analysis workflows tied to fetal tissue models.
Stock impact
Danaher's Biotechnology segment (~$7B revenue) spans bioprocessing and lab tools; fetal tissue research exposure is concentrated in a subset of academic labs. The impact is modest given Danaher's diversification across diagnostics and bioprocessing. 7-day change of +0.72% suggests no acute investor concern specific to this bill.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
ADVANCED TECHNOLOGY INTERNATIONAL: $19.6M Department of Health and Human Services Contract
ACUITY-CHS, LLC: $15.0M Department of Homeland Security Contract
Preventing Illegal Laboratories and Protecting Public Health Act of 2026
Genomic Answers for Children’s Health Act of 2026
SEPSIS Act
Meeting Demand for Organic Produce Act
OLH TECHNICAL SERVICES, LLC: $12.2M Department of Justice Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →